LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.41 USD | -1.13% |
|
+2.23% | -24.53% |
| 23/04 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
| 22/04 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,735 | 7,175 | 8,357 | 10,938 | 8,261 | - | - |
| Enterprise Value (EV) 1 | 3,233 | 6,446 | 7,855 | 9,959 | 7,333 | 7,426 | 7,055 |
| P/E ratio | -22 x | -34 x | -35.7 x | -40.9 x | -43.4 x | -146 x | 83.9 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 49.4 x | 79.9 x | 71.4 x | 38.4 x | 14.2 x | 7.69 x | 5.04 x |
| EV / Revenue | 42.7 x | 71.8 x | 67.1 x | 34.9 x | 12.6 x | 6.91 x | 4.31 x |
| EV / EBITDA | -14.6 x | -17.9 x | -17.7 x | -25.4 x | -22.8 x | -114 x | 34.2 x |
| EV / FCF | -12 x | -26.6 x | -33.1 x | -24.1 x | -23.2 x | -179 x | 36.3 x |
| FCF Yield | -8.31% | -3.76% | -3.02% | -4.15% | -4.31% | -0.56% | 2.75% |
| Price to Book | 26.7 x | 30.5 x | - | 17.5 x | 6.51 x | 6.28 x | 4.37 x |
| Nbr of stocks (in thousands) | 1,32,638 | 1,53,946 | 1,67,403 | 1,81,789 | 1,81,911 | - | - |
| Reference price 2 | 28.16 | 46.61 | 49.92 | 60.17 | 45.41 | 45.41 | 45.41 |
| Announcement Date | 18/03/21 | 18/03/22 | 30/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 75.68 | 89.79 | 117 | 285.1 | 583.3 | 1,074 | 1,638 |
| EBITDA 1 | -220.8 | -360.6 | -443.2 | -392.1 | -321.2 | -65.22 | 206.2 |
| EBIT 1 | -229.2 | -373 | -455.8 | -412.6 | -336.4 | -102.2 | 223 |
| Operating Margin | -302.87% | -415.44% | -389.58% | -144.69% | -57.67% | -9.51% | 13.62% |
| Earnings before Tax (EBT) 1 | -307.6 | -386.2 | -445.7 | -520.1 | -317.8 | -90.9 | 236.1 |
| Net income 1 | -303.5 | -386.2 | -446.3 | -518.3 | -316.7 | -92.85 | 211.8 |
| Net margin | -401.02% | -430.12% | -381.48% | -181.75% | -54.3% | -8.64% | 12.93% |
| EPS 2 | -1.280 | -1.370 | -1.400 | -1.470 | -1.045 | -0.3114 | 0.5412 |
| Free Cash Flow 1 | -268.8 | -242.4 | -237 | -413.4 | -316.1 | -41.57 | 194.1 |
| FCF margin | -355.14% | -269.92% | -202.57% | -144.97% | -54.19% | -3.87% | 11.85% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 94.12% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 91.67% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 18/03/21 | 18/03/22 | 30/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 16.88 | 39 | 40.83 | 11.97 | 36.34 | 73.33 | 96.01 | 79.46 | 142.7 | 125.1 | 131.7 | 178.7 | 178.9 |
| EBITDA 1 | -82.13 | -114.2 | - | -116.1 | - | - | -53.64 | - | -63.85 | -120.6 | -107.9 | -93.5 | -77.21 |
| EBIT 1 | -86.77 | -117.5 | -76 | -125.5 | -106.9 | -104.3 | -56.82 | -141 | -60.35 | -87.05 | -100.8 | -91.47 | -87.64 |
| Operating Margin | -513.98% | -301.22% | -186.16% | -1,048.6% | -294.09% | -142.25% | -59.18% | -177.43% | -42.3% | -69.59% | -76.51% | -51.19% | -48.98% |
| Earnings before Tax (EBT) 1 | -124.8 | -88.33 | -41.09 | -193.1 | -112 | -198.8 | -62.5 | -146.8 | -69.29 | -90.67 | -98.08 | -84.61 | -91.64 |
| Net income 1 | -124.8 | -88.33 | -41.09 | -193.2 | -112.1 | -199.1 | -62.21 | -144.8 | -69.04 | -90.46 | -97.69 | -83.82 | -91.79 |
| Net margin | -738.96% | -226.53% | -100.64% | -1,614.13% | -308.51% | -271.55% | -64.79% | -182.24% | -48.38% | -72.32% | -74.16% | -46.9% | -51.3% |
| EPS 2 | -0.4300 | -0.3000 | -0.1300 | -0.6200 | -0.3400 | -0.5700 | -0.1700 | -0.4000 | -0.1783 | -0.2792 | -0.2919 | -0.2366 | -0.2475 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 16/11/21 | 18/03/22 | 01/06/22 | 17/02/23 | 18/05/23 | 15/08/23 | 20/11/23 | 11/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 502 | 729 | 501 | 979 | 928 | 835 | 1,206 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -269 | -242 | -237 | -413 | -316 | -41.6 | 194 |
| ROE (net income / shareholders' equity) | -284% | -103% | -59.1% | -51.9% | -32.9% | -5.7% | 13.9% |
| ROA (Net income/ Total Assets) | -44.3% | -42% | -36.4% | -32.6% | -26.4% | -3.15% | 11.1% |
| Assets 1 | 684.9 | 919.7 | 1,225 | 1,590 | 1,198 | 2,950 | 1,913 |
| Book Value Per Share 2 | 1.050 | 1.530 | - | 3.440 | 6.980 | 7.230 | 10.40 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 45.7 | 43.9 | 35.7 | 20.1 | 42.2 | 42.3 | 36.1 |
| Capex / Sales | 60.45% | 48.9% | 30.54% | 7.04% | 7.23% | 3.93% | 2.2% |
| Announcement Date | 18/03/21 | 18/03/22 | 30/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
45.93
USD
Average target price
86.34
USD
Spread / Average Target
+87.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.53% | 8.36B | |
| -1.43% | 103B | |
| +8.96% | 101B | |
| +4.40% | 23.07B | |
| -12.15% | 22.23B | |
| -4.36% | 18.05B | |
| -39.98% | 17.18B | |
| -10.04% | 16.94B | |
| +6.79% | 14.07B | |
| +38.61% | 12.35B |
- Stock Market
- Equities
- LEGN Stock
- Financials Legend Biotech Corporation
